A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

Phase 1 Completed 40 enrolled Suzhou Ribo Life Science Co. Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single (Part A) and repeated dose (Part B) escalation, phase I clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) of RBD1016 in subjects with chronic HBV infection.

Timeline

Start: 2021-08-09
Primary completion: 2023-10-25
Completion: 2023-10-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RBD1016	Unknown	—	Subcutaneous
Background	Entecavir	Small molecule	—	Oral

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

Summary

Timeline

Drugs

Indications